0.0243USD-19.00%Mkt Cap: 1.22M USDP/E: —Last update: 2026-06-01
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. Its drug delivery and antisense technology is the DNAbilize, a platfo…
Industry Peers
BiotechnologyIndicators:|
Key Statistics
Company
Market Cap1.22M USD
Enterprise Value2.11M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-9.89M USD
Revenue/Share—
Last Price0.0243 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees1
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.01
PEG—
EV/EBITDA-0.39
EV/Revenue—
P/S—
P/B-0.03
EPS (TTM)-1.14
EPS (Forward)-4.04
52W Range
0.01006% of range0.2300
52W High0.2300 USD
52W Low0.0100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-6424.68%
ROA-254.80%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.57M USD
CapEx (TTM)—
FCF Margin—
FCF Yield187.21%
Net Debt499.00K USD
Net Debt/EBITDA-0.09
Balance Sheet
Debt/Equity0.54
Current Ratio0.07
Quick Ratio0.00
Book Value/Sh-0.9080 USD
Cash/Share0.0000 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateJan 18, 2019
Splits
Last Split1:20
Split DateFeb 23, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.50.30M
Float49.91M
Insiders0.00%
Institutions0.87%
Short Interest
Short Ratio0.4d
Short % Float1.38%
Short % Out.1.38%
Shares Short79.35K
Short (prev mo.)249.95K
Technical
SMA 500.0540 (-55.0%)
SMA 2000.0709 (-65.8%)
Beta-0.28
S&P 52W Chg27.94%
Avg Vol (30d)37.37K
Avg Vol (10d)55.81K
Technical Indicators
RSI (14)39.5
MACD-0.0067
MACD Signal-0.0066
MACD Hist.-0.0001
BB Upper0.0674 USD
BB Middle0.0418 USD
BB Lower0.0161 USD
BB Width122.82%
ATR (14)0.0086 USD
Vol Ratio (20d)0.18x